Boston, MA, United States of America

Fabien Rodier

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Valo Health, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fabien Rodier. Retrieved from https://idiyas.com/inventor/fabien-rodier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Fabien Rodier: Inventor in Pharmaceutical Chemistry

Introduction

Fabien Rodier is an inventor associated with Boston, Massachusetts, and Valo Health, Inc. His patent work concerns chemical processes and compounds relevant to pharmaceutical research.

Latest Patents

Rodier is named on 1 patent: “Process for Preparing 6-Substituted-1-(2H)-Isoquinolinones and Intermediate Compound.” The invention describes substituted isoquinoline oxide compounds and a process for preparing them. These compounds can serve as intermediates in making 6-substituted-1-(2H)-isoquinolinones, which are described as inhibitors of the enzyme Rho-kinase or as intermediates for preparing further Rho-kinase inhibitors.

Career Highlights

Rodier’s patent reflects work on synthetic methods and intermediate compounds that may support the development of Rho-kinase inhibitors. The available information identifies Valo Health, Inc. as his company affiliation.

Collaborations

Xavier Bon and Boris Camuzat-Dedenis are identified as Rodier’s coworkers.

Conclusion

Fabien Rodier’s documented invention focuses on preparing chemical intermediates connected to Rho-kinase inhibitors, highlighting his contribution to pharmaceutical chemistry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…